Finance

Lists
Why is RXRX down 7,49%?
Dive Deeper
RXRX:NASDAQ
Recursion Pharmaceuticals Inc
3,95 $
-7,49%
(-0,32) 1D
4,01 $
+1,52% (+0,060)
Pre-market
Closed: 8 հոկ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RXRX...
Open
4,19 $
High
4,20 $
Low
3,79 $
Mkt. cap
2,11 մլրդ
Avg. vol.
23,13 մլն
Volume
146,46 հզր
52-wk high
7,18 $
52-wk low
2,77 $
EPS
-1,04 $
Beta
1,04
Shares outstanding
535,34 մլն
No. of employees
600
Open
4,19 $
High
4,20 $
Low
3,79 $
Mkt. cap
2,11 մլրդ
Avg. vol.
23,13 մլն
Volume
146,46 հզր
52-wk high
7,18 $
52-wk low
2,77 $
EPS
-1,04 $
Beta
1,04
Shares outstanding
535,34 մլն
No. of employees
600
News stories
From web sources and news partners
About Recursion Pharmaceuticals Inc
CEONajat Khan
Employees600
Founded2013
HeadquartersՍոլթ Լեյք Սիթի, Յուտա, Միացյալ Նահանգներ
Sector-
Websiterecursion.com
Analyst ratings
Based on 5 analysts giving stock ratings to RXRX in the past 3 months
Buy
Buy
2
Hold
3
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for RXRX in the last 3 months.
Highest
Current 3,95 $
8,00 $ (+102,53%)
Average
6,65 $ (+68,35%)
Lowest
5,30 $ (+34,18%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Hold
Maintained
-
-
09/21/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
09/15/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
5,30 $
+34,2%
08/17/2026
Brendan Smith
TD Cowen
Hold
Maintained
-
-
08/05/2026
Gil Blum
Needham
Buy
Maintained
8,00 $
+102,5%
08/05/2026
Last report
05 օգս, 2026 թ.
Fiscal period
Q2 2026
-0,25 $ / -0,23 $
-6,84%miss
Revenue / Est. (USD)
7,67 մլն / 11,96 մլն
-35,89%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
5,18 մլն
35,54 մլն
6,47 մլն
7,67 մլն
Cost of goods sold
135,75 մլն
110,22 մլն
100,39 մլն
101,10 մլն
Cost of revenue
135,75 մլն
110,22 մլն
100,39 մլն
101,10 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
41,63 մլն
42,17 մլն
34,59 մլն
41,53 մլն
Operating expense
41,63 մլն
42,17 մլն
34,59 մլն
41,53 մլն
Total operating expenses
177,38 մլն
152,39 մլն
134,98 մլն
142,64 մլն
Operating income
-172,20 մլն
-116,85 մլն
-128,50 մլն
-134,97 մլն
Other non operating income
5,24 մլն
-6,03 մլն
784,00 հզր
-1,04 մլն
EBT including unusual items
-162,25 մլն
-108,10 մլն
-122,11 մլն
-131,01 մլն
EBT excluding unusual items
-162,25 մլն
-116,62 մլն
-122,11 մլն
-131,01 մլն
Income tax expense
3,00 հզր
20,00 հզր
-4,60 մլն
-1,00 հզր
Effective tax rate
-
-0,02%
3,77%
-
Other operating expenses
-
-
-
-
Net income
-162,25 մլն
-108,12 մլն
-117,50 մլն
-131,00 մլն
Net profit margin
-3 135,32%
-304,24%
-1 815,57%
-1 708,02%
Earnings per share
-0,36
-0,21
-0,22
-0,25
Interest and investment income
5,54 մլն
6,26 մլն
5,96 մլն
5,31 մլն
Interest expense
-833,00 հզր
-
-350,00 հզր
-309,00 հզր
Net interest expenses
4,71 մլն
6,26 մլն
5,61 մլն
5,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-151,16 մլն
-97,37 մլն
-108,83 մլն
-116,80 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps